Piscitelli Dominic sold $1.1M of ORIC

Piscitelli Dominic (Chief Financial Officer) sold 77,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.69 ($1.05M total) on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Piscitelli Dominic
Published Aug 28, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Bearish
medium confidence
Mentioned
$ORIC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative signal, but the size is modest.

02

Market read

Primary relevance is to ORIC shareholders; limited broader market impact.

03

What to watch

Potential upcoming clinical data releases or financing events that could offset the sell‑off.

Relevance 5/10Novelty 4/10Timing: filed today (2026‑08‑28)

Background

Form 4 filing discloses insider transactions; CFO sales are monitored for potential signals.

Company-level read

Ticker impact

$ORICBearishMedium confidence
Context

CFO Piscitelli Dominic sold 77,000 shares for $1.05M via a 10b5‑1 plan, reducing his stake to 69,828 shares.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

CFO insider sales are material but the amount is modest relative to market cap; market may react lightly.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and not sector‑wide.

No significant regional effect; limited to Oric shareholders.

Low global relevance.

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals, so price may remain stable.

Key entities

  • Oric Pharmaceuticals, Inc.

    US‑listed biotech company (ticker ORIC).

  • Piscitelli Dominic

    Chief Financial Officer of Oric.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo